Patents by Inventor Luc Roland Desnoyers

Luc Roland Desnoyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11992528
    Abstract: The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: May 28, 2024
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Tony W. Liang, Andrei William Konradi, Shweta Singh
  • Publication number: 20240076374
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 18, 2023
    Publication date: March 7, 2024
    Inventors: James William WEST, Jason Gary SAGERT, Jonathan Alexander TERRETT, Annie Yang WEAVER, Luc Roland DESNOYERS, Shweta SINGH
  • Patent number: 11890354
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 6, 2024
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 11753466
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 12, 2023
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Publication number: 20220306759
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: February 8, 2022
    Publication date: September 29, 2022
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • Publication number: 20220289853
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 22, 2021
    Publication date: September 15, 2022
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu
  • Publication number: 20220242949
    Abstract: The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capable of binding CD166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD166 antibody or antigen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (“ICD”) of CD166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD166. In various embodiments, an anti-CD166 antibody or antigen-binding polypeptide is useful in a method of detecting or treating a condition or disease.
    Type: Application
    Filed: November 9, 2021
    Publication date: August 4, 2022
    Inventors: Luc Roland Desnoyers, Amy Grace DuPage
  • Publication number: 20220088192
    Abstract: The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.
    Type: Application
    Filed: April 9, 2021
    Publication date: March 24, 2022
    Inventors: Henry Bernard LOWMAN, Luc Roland DESNOYERS, Tony W. LIANG, Andrei William KONRADI, Shweta SINGH
  • Patent number: 11267896
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: March 8, 2022
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • Patent number: 11220544
    Abstract: The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or antigen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (“ICD”) of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypeptide is useful in a method of detecting or treating a condition or disease.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: January 11, 2022
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Luc Roland Desnoyers, Amy Grace DuPage
  • Patent number: 11180562
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: November 23, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu
  • Publication number: 20210025877
    Abstract: The invention provides methods and kits for qualitatively and/or quantitatively analyzing activation and other properties of activatable antibody therapeutic in biological samples, including tissues and/or biofluid samples. The invention also relates to methods of using a capillary-based immunoassay platform to qualitatively and/or quantitatively analyze levels of activation in biological samples, including tissues and/or biofluid samples.
    Type: Application
    Filed: July 20, 2018
    Publication date: January 28, 2021
    Inventors: Olga VASILJEVA, Stephen James MOORE, Bruce HOWNG, Susan K. LYMAN, Luc Roland DESNOYERS
  • Publication number: 20210023243
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: June 4, 2020
    Publication date: January 28, 2021
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Publication number: 20200291113
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 20, 2019
    Publication date: September 17, 2020
    Inventors: James William WEST, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Publication number: 20200270350
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 12, 2019
    Publication date: August 27, 2020
    Inventors: Henry Bernard LOWMAN, Luc Roland Desnoyers, Shouchun Liu
  • Patent number: 10745481
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: August 18, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Publication number: 20200223919
    Abstract: The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or antigen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (“ICD”) of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypeptide is useful in a method of detecting or treating a condition or disease.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 16, 2020
    Inventors: Luc Roland Desnoyers, Amy Grace DuPage
  • Patent number: 10709799
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: July 14, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 10577420
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 3, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Patent number: 10568977
    Abstract: The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: February 25, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Luc Roland Desnoyers, Tony W. Liang, Annie Yang Weaver